Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 13/20 | 0.62 |
| ▸ | TAF1 | P21675 | 2/20 | 0.62 |
| ▸ | MAPK7 | Q13164 | 7/20 | 0.61 |
| ▸ | LRRK2 | Q5S007 | 5/20 | 0.61 |
| ▸ | BRDT | Q58F21 | 8/20 | 0.61 |
| ▸ | PLK1 | P53350 | 8/20 | 0.61 |
| ▸ | DCLK1 | O15075 | 2/20 | 0.59 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.58 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.55 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10098786 | 1.00 | BRD4 (0.62) | BRD4TAF1MAPK7LRRK2BRDT | |
| SCHEMBL618948 | 0.89 | PLK1 (0.74) | BRD4TAF1MAPK7LRRK2BRDT | |
| SCHEMBL10098805 | 0.89 | PLK1 (0.74) | BRD4TAF1MAPK7LRRK2BRDT | |
| SCHEMBL21755670 | 0.86 | MAPK7 (0.61) | BRD4TAF1MAPK7LRRK2BRDT | |
| SCHEMBL10098783 | 0.86 | BRD4 (0.73) | BRD4TAF1MAPK7BRDTPLK1 | |
| SCHEMBL616163 | 0.86 | BRD4 (0.73) | BRD4TAF1MAPK7BRDTPLK1 | |
| SCHEMBL19105962 | 0.83 | BRD4 (0.60) | BRD4TAF1MAPK7LRRK2BRDT | |
| SCHEMBL619272 | 0.81 | LRRK2 (0.65) | BRD4MAPK7LRRK2PLK1DCLK1 | |
| SCHEMBL10098728 | 0.81 | LRRK2 (0.65) | BRD4MAPK7LRRK2PLK1DCLK1 | |
| SCHEMBL10098781 | 0.80 | PLK1 (0.69) | BRD4TAF1MAPK7BRDTPLK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10570154-B2 | Pyrimido-diazepinone kinase scaffold compounds and methods of treating disorders | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2020-02-25 | — | — | US | claimed |
| US-20180362545-A1 | PYRIMIDO-DIAZEPINONE KINASE SCAFFOLD COMPOUNDS AND METHODS OF TREATING DISORDERS | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2018-12-20 | — | — | US | claimed |
| US-20120040961-A1 | PYRIMIDO-DIAZEPINONE KINASE SCAFFOLD COMPOUNDS AND METHODS OF TREATING DISORDERS | DANA-FARBER CANCER INSTITUTE (US) | 2012-02-16 | — | — | US | claimed |
| EP-3828185-A2 | PYRIMIDO-DIAZEPINONE KINASE SCAFFOLD COMPOUNDS AND METHODS OF TREATING DISORDERS | Dana Farber Cancer Institute, Inc. (US) | 2021-06-02 | — | — | EP | disclosed |
| US-10383847-B2 | Compositions and methods to improve the therapeutic benefit of indirubin and analogs thereof, including meisoindigo | BROWN DENNIS M (US) | 2019-08-20 | — | — | US | disclosed |
| US-10081639-B2 | Pyrimido-diazepinone kinase scaffold compounds and methods of treating disorders | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2018-09-25 | — | — | US | disclosed |
| US-20170260208-A1 | PYRIMIDO-DIAZEPINONE KINASE SCAFFOLD COMPOUNDS AND METHODS OF TREATING DISORDERS | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2017-09-14 | — | — | US | disclosed |
| US-20160243077-A1 | COMPOSITIONS AND METHODS TO IMPROVE THE THERAPEUTIC BENEFIT OF INDIRUBIN AND ANALOGS THEREOF, INCLUDING MEISOINDIGO | BROWN DENNIS M (US) | 2016-08-25 | — | — | US | disclosed |
| US-20160122357-A1 | PYRIMIDO-DIAZEPINONE KINASE SCAFFOLD COMPOUNDS AND METHODS OF TREATING DISORDERS | DANA-FARBER CANCER INSTITUTE, INC. | 2016-05-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10081639-B2 | Pyrimido-diazepinone kinase scaffold compounds and methods of treating disorders | BRSK2, STK3, BRSK1 | BRD4 614/4885TAF1 1629/4885MAPK7 253/4885 |
| US-20120040961-A1 | PYRIMIDO-DIAZEPINONE KINASE SCAFFOLD COMPOUNDS AND METHODS OF TREATING DISORDERS | BRSK2, BRSK1, TAOK3 | BRD4 555/4885TAF1 1732/4885MAPK7 263/4885 |
| US-10383847-B2 | Compositions and methods to improve the therapeutic benefit of indirubin and analogs thereof, including meisoindigo | NEK9, NEK7, NEK3 | BRD4 396/4885TAF1 2788/4885MAPK7 295/4885 |
| US-20160122357-A1 | PYRIMIDO-DIAZEPINONE KINASE SCAFFOLD COMPOUNDS AND METHODS OF TREATING DISORDERS | BRSK2, STK3, BRSK1 | BRD4 614/4885TAF1 1629/4885MAPK7 253/4885 |
| US-10570154-B2 | Pyrimido-diazepinone kinase scaffold compounds and methods of treating disorders | BRSK2, STK3, BRSK1 | BRD4 614/4885TAF1 1629/4885MAPK7 253/4885 |
| US-20180362545-A1 | PYRIMIDO-DIAZEPINONE KINASE SCAFFOLD COMPOUNDS AND METHODS OF TREATING DISORDERS | BRSK2, STK3, BRSK1 | BRD4 614/4885TAF1 1629/4885MAPK7 253/4885 |
| US-20160243077-A1 | COMPOSITIONS AND METHODS TO IMPROVE THE THERAPEUTIC BENEFIT OF INDIRUBIN AND ANALOGS THEREOF, INCLUDING MEISOINDIGO | NEK9, NEK7, NEK3 | BRD4 396/4885TAF1 2788/4885MAPK7 295/4885 |
| US-20170260208-A1 | PYRIMIDO-DIAZEPINONE KINASE SCAFFOLD COMPOUNDS AND METHODS OF TREATING DISORDERS | BRSK2, STK3, BRSK1 | BRD4 614/4885TAF1 1629/4885MAPK7 253/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.